The clascoterone trials studied patients 12 and older with moderate-to-severe facial acne, not a dedicated adult persistent-acne group. Adults with chronic hormonal patterns, treatment-resistant disease, or severe truncal-only acne fall outside the directly tested population. Clascoterone 1% cream, sold as Winlevi, is a topical androgen-receptor inhibitor that blocks androgen signals in skin. According to the FDA approval notice reported by BioSpace, regulators approved twice-daily use for acne vulgaris in patients 12 and older in August 2020 the FDA approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the main trials tested
- Who was left out of the pivotal trials
- What longer use and body acne add
- How adults with persistent acne can act
- Frequently Asked Questions
What the main trials tested
Two identical 12-week Phase 3 trials randomized 1,440 patients with moderate-to-severe facial acne. Efficacy was analyzed in 1,421 patients aged 12 and older, with about 60-64% female participants, as reported by JAMA Dermatology via MedicalBag the Phase 3 trial summary. Pooled success meant clear or almost clear skin plus a two-grade improvement on the Investigator's Global Assessment.
The Pharmaceuticals narrative review reported 19.9% success with clascoterone versus 7.7% with vehicle, plus greater lesion-count reductions the pooled efficacy review. The result supports a real drug effect for facial acne over 12 weeks. The absolute success rate also stayed modest, so many patients still had active acne at week 12.
Who was left out of the pivotal trials
The pivotal trials studied only facial acne. They excluded more than two facial nodules, nodulocystic acne, other facial skin disease, and recent topical or systemic acne treatments, according to the JAMA Dermatology report on PMC the pivotal-trial eligibility report. Excluded recent treatments included retinoids, antibiotics, steroids, and spironolactone.
That matters for adults who cycle through prescription combinations or maintain hormonal therapy. No separate cohort enrolled adults with persistent, late-onset, treatment-resistant, pregnant, lactating, or severe truncal-only disease. Enrollment began at age 9 to 12 and older, so findings for older adults come from the broader age-inclusive sample rather than a persistent-acne subgroup.
What longer use and body acne add
A nine-month open-label extension enrolled Phase 3 completers aged 9 and older. For the first time, it allowed twice-daily treatment of truncal acne when present, with total exposure up to 12 months. That extension gives the best available picture of longer exposure and body-area use.
It does not replace a controlled truncal-acne trial or a trial focused on adult persistent acne. The DailyMed label limits the indication to age 12 and older, warns about HPA-axis suppression risk and local irritation, and lists no FDA labeled contraindications. Practical use therefore centers on facial disease in eligible adolescents and adults, with body use discussed only when facial disease and age criteria fit.
How adults with persistent acne can act
Start by matching your pattern to the studied pattern. Facial moderate-to-severe acne without nodules or cysts fits best, while isolated chest or back disease, severe nodular breakouts, and unstable combination regimens fit least. Bring a short history to the visit.
Include prior retinoids, antibiotics, hormonal treatments, steroids, current facial products, and pregnancy or breastfeeding plans. The 2024 AAD acne guideline conditionally recommends topical clascoterone on a case-by-case basis, while strongly recommending benzoyl peroxide, retinoids, topical antibiotic combinations, and oral isotretinoin for severe disease. That framework favors a targeted trial in matching facial cases and a broader plan for resistant or severe persistent acne.
- Ask whether facial disease qualifies under the 12-and-older indication
- Ask how truncal breakouts will be managed alongside facial treatment
- Ask what to pause or wash out before starting
- Ask when to review irritation, dryness, or lack of response
- Ask where benzoyl peroxide, retinoids, combinations, or isotretinoin fit for severe disease
Frequently Asked Questions
I am over 30 with jawline breakouts. Was my group tested?
No separate adult persistent-acne group was enrolled. Your dermatologist must judge from results in the broader 12-and-older facial-acne population.
Can I use it only on my back?
The controlled trials treated facial acne only. Truncal treatment appeared only when present during the open-label extension.
Do I need to stop other acne drugs first?
The pivotal trials excluded recent retinoids, antibiotics, steroids, and spironolactone. Ask your prescriber what to continue, pause, or sequence.
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne
- High-Glycemic Diets and Acne Evidence Revisited in 2026: What the Review Supports and Does Not Prove for Adults With Persistent Acne
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: How Adults With Persistent Acne Can Avoid Overreading the Headline